With a clear focus on alcohol abuse and binge drinking, Clearmind Medicine Inc.’s (CSE:CMND) first drug candidate addresses very common (and costly) afflictions which to date, have limited solutions
SmallCapPower | July 5, 2021: Clearmind Medicine Inc. (CSE:CMND) is a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic derived therapeutics to solve widespread and under-served health problems including alcohol use disorder. Its primary objective is to research and develop compounds derived from psychedelics and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of two patent families, one for binge behaviour regulators and the other for an alcoholic beverage substitute. Within these two families the Company has two U.S. patents, one European patent, and allowed applications in China and India and pending divisional applications in Europe and the U.S. related to binge behavior regulators; and a European patent and pending applications in the U.S. China and India related to the alcohol beverage substitute family.
With a clear focus on alcohol abuse and binge drinking, Clearmind’s first drug candidate addresses very common (and costly) afflictions which to date, have limited solutions.
With traditional therapies lacking, Clearmind’s psychedelic-based solutions are set to revolutionise this space.
According to the World Health Organization, alcohol consumption contributes to three million deaths each year globally, in addition to disabilities and poor health of millions of people.
Clearmind Medicine’s psychedelic derived therapeutics revolves around 5-Methoxy-2-aminoindane (MEAI), a psychoactive molecule, exerting a euphoric alcohol-like experience and a reduced desire to consume alcoholic beverages. MEAI shows a high safety profile in pre-clinical studies and a promising efficacy, with potential to change the lives of millions who struggle with alcohol.
MEAI holds the promise to break the binge-drinking vicious cycle by potentially innervating neural pathways such as 5-HT1A, which leads to what the Company calls “sensible behaviour”.
Clearmind contends that the literature shows that 5-HT1A receptors are associated with controlling craving behaviour across the board. This indicates that MEAI may have a wide range of applications beyond binge drinking.
Ubika Research/SmallCapPower has received compensation from Clearmind Medicine to provide analyst research coverage. For full disclosure please visit here >>
To read our full disclosure, please click on the button below:
 first drug candidate addresses very common (and costly) afflictions which to date, have limited solutions.){kind=link}